MetaCap

Nu Skin Enterprises Inc. (NUS)

NYSE: NUSHealth CareOther PharmaceuticalsUSD

3.80+0.03 (+0.80%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NUS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$184.98M
EPS (TTM)
-$4.86
Dividend yield
6.32% ($0.24)
Ex-dividend date
Aug 28, 2026
52-week range
3.75 – 11.67
Day range
3.75 – 3.84
Volume / Avg
794.07K / 533.16K
Beta
—

52-week range

$3.75$11.67

NUS stock today

Shares of Nu Skin Enterprises (NUS) finished higher on Nov 20 at $3.80, a gain of 0.80% or $0.03 per share, versus the S&P 500's 3.70% decline. At this level, NUS sits near the bottom of its 52-week range of $3.75 to $11.67: 67.4% below the high, set on Jan 16, 2026 and 1.3% above the low. NUS is down 60.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.1%.

Nu Skin Enterprises has posted a net loss over the last twelve months (EPS of -$4.86), so its P/E ratio is not meaningful. Nu Skin Enterprises pays an annual dividend of $0.24 per share, a 6.32% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Nu Skin Enterprises

Company profile

Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa, ageLOC LumiSpa iO, and Nu Skin RenuSpa iO; ageLOC TruFace and ageLOC LumiSpa cleansers and devices; Prysm iO, a data-enabled wellness device; and Nutricentials beauty and Beauty Focus wellness brands. The company also provides wellness products, such as ageLOC TRME, LifePak, and Beauty Focus.

Industry
Other Pharmaceuticals
CEO
Mr. Ryan S. Napierski
Headquarters
Provo, UT
Employees
2,800
IPO year
1996
Website
nuskin.com

Financial highlights

Full financials

In fiscal 2025, Nu Skin Enterprises generated $1.49 billion in revenue, down 14.3% from fiscal 2024, its first annual decline since 2024. Net income was $160.2 million, for a net margin of 10.8% versus a median of 4.7% in the prior 5 years. Gross margin was 69.4% (up from 68.2%) and operating margin 4.4%.

Nu Skin Enterprises annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.49B$1.73B$1.97B$2.23B$2.70B
Growth-14.26%-12.04%-11.53%-17.44%+4.41%
Net income$160.20M$-146.59M$8.60M$104.78M$147.27M
EPS (diluted)$3.18$-2.95$0.17$2.07$2.86

Analyst forecast

Forecast

Consensus

strong_buy

Avg. price target

$12.48+228.42%

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.34 vs $0.21
Surprise
+61.90%

Dividends

Dividend history
Annual dividend
$0.24
Last payment
$0.06
Ex-dividend date
Aug 28, 2026

NUS news

All NUS news

Nu Skin Enterprises peers

Health Care sector
NUS peer companies
CompanyPrice% ChgMarket capCompare
ESYNEnerSyn Global Inc.1.11-0.89%$37.44Mvs NUS
COSMCosmos Health Inc.2.81-2.09%$14.14Mvs NUS
MEDSDataMeds AI Inc.1.34+84.14%$7.67Mvs NUS
HKPDCellyan Biotechnology Co. Ltd Class A1.38+2.60%$3.40Mvs NUS
HLFHerbalife Ltd.15.53-0.26%$1.63Bvs NUS
CAHCardinal Health Inc.272.81+0.17%$63.06Bvs NUS
CORCencora Inc.339.09-0.63%$64.71Bvs NUS
MCKMcKesson Corporation1,069.43+0.68%$123.47Bvs NUS

Indexes, lists and sector

Nu Skin Enterprises stock FAQ

What is Nu Skin Enterprises's stock price today?

NUS last traded at $3.80 as of Nov 20, 4:00 PM EST, up 0.80% on the day. Prices are delayed at least 15 minutes.

Does Nu Skin Enterprises pay a dividend?

Yes. Nu Skin Enterprises pays $0.24 per share annually, a 6.32% yield. The most recent dividend of $0.06 had an ex-dividend date of Aug 28, 2026.

Who is Nu Skin Enterprises's CEO?

Mr. Ryan S. Napierski is the chief executive officer of Nu Skin Enterprises Inc., which has about 2,800 employees.

What is the NUS 52-week high?

The 52-week high for NUS is $11.67 and the 52-week low is $3.75. The stock is currently 67.4% below its high.

Compare NUS